Nes-Ziona, Israel, AUG 18, 2018 – Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that Dr. Mohamad Mothy has joined its post bone marrow transplantation complications – clinical advisory board.
Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France). Dr. Mohty is also President of the European Society for Blood and Marrow Transplantation (EBMT).
Professor Dr. Mohamed Mohty is also head of a translational research team (INSERM) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of immunomodulatory agents. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of multiple myeloma. He also serves on the board of the EBMT, and the “Intergroupe Francophone du Myelome” (IFM).
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visit http://www.enlivex.com.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.